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In this issue, Dereure and colleagues (p. 614) present a study com-
paring the clonality patterns in the skin and peripheral blood of
patients with mycosis fungoides (MF) using polymerase chain re-
action (PCR) analysis of the T-cell receptor (TCR) gamma gene
(Dereure et al, 2003). The authors found a good concordance be-
tween the size of the dominant ampli¢ed clone in involved blood
and skin biopsy specimens but a relatively poor correlation be-
tween clinical response and the persistence of detectable TCR-
gamma clones. This ¢nding is likely related to the fact that
current MF therapies are rarely curative and the sensitivity of the
PCR method easily detects residual disease that may not be clini-
cally apparent. The authors also detected TCR-gamma clonal re-
arrangements in the blood that appear unrelated to the dominant
skin tumor clone, in a subset of MF patients.
This study demonstrates some of the problems inherent in the
use of the TCR-gamma PCR assay as a method for staging and
following outcomes in MF patients. The work also highlights the
importance of acknowledging the limitations of clonality assays
in evaluating T-cell disorders and the need to de¢ne the role and
range of future uses of molecular testing. Below, we summarize
the several di¡erent goals for undertaking clonality studies in MF
and how other methodologies might be used to approach them.
USE OF CLONALITY STUDIES TO DIFFERENTIATE
BENIGN FROM MALIGNANT CUTANEOUS T-CELL
DISORDERS
In a number of studies published over the last 15 years, it has been
shown that dominant T-cell clones can be detected by either
TCR Southern blot or PCR-based methods in entities (e.g., lym-
phomatoid papulosis, Mucha-Habermann disease or psoriasis)
that had been generally regarded as benign or in£ammatory in
nature (Weiss et al, 1986). In contrast, clinically obvious T-cell tu-
mors can sometimes lack demonstrable clonal TCR gene rearran-
gements by either Southern blot or PCR analysis (Weiss et al,
1988; Vega et al, 2002). These studies show that the presence or
absence of T-cell clonality cannot be exactly equated with the
clinical categorization of lesions as benign or malignant.
There are also technical problems with all current TCR clon-
ality assays. TCR-beta or -delta Southern blot analyses require
adequate amounts of high-quality DNA and will fail to detect
clonal T-cell populations when they represent less than 1^5% of
the cells analyzed. TCR-gamma PCR assays can show false-
positive ‘‘pseudoclonal’’ ampli¢ed peaks and will fail to detect T-
cell clones that have undergone point mutation within the TCR
primer-binding sequences. Nonetheless, with good-quality mate-
rial,TCR-gamma PCR and TCR-beta Southern blot have a con-
cordance rate of 80^90% in most laboratories. Thus, conceding
the limitations above, routine TCR clonality studies on skin
biopsies can be highly useful in con¢rming a clinical and patho-
logic suspicion of cutaneous T-cell lymphoma (Dadej et al, 2001).
USE OF CLONALITY STUDIES TO STAGE MF PATIENTS
AND PREDICT PROGRESSION
A number of studies have suggested that TCR clonality assays
might be used to stage MF patients at extracutaneous sites. How-
ever, in a large study using TCR-gamma PCR analysis, Delfau-
Larue and colleagues convincingly demonstrated that peripheral
blood samples commonly show ampli¢ed PCR products that
are di¡erent from the dominant skin clone, thus giving mislead-
ing staging results (Delfau-Larue et al, 2000). Furthermore, in that
study, nearly all MF patients with a common clone detected by
PCR analysis had clinically evident erythroderma and tumor
cells identi¢ed on review of the peripheral blood smear. Thus,
TCR molecular studies contributed little useful clinical informa-
tion. In this regard, we have found that £ow cytometric analysis
of peripheral blood, even with a limited T-cell panel, is highly
e¡ective in demonstrating and quantifying small numbers of
circulating tumor cells (Washington et al, 2002). Therefore, we
believe that £ow cytometry is a clearly superior technology for
staging MF patients at extracutaneous sites.
The nature of the peripheral blood TCR-gamma clones which
are di¡erent from the dominant MF clone have not been deter-
mined in most studies. However, their increased detection fre-
quency in older patient suggests that they may be coming from
the benign oligoclonal and clonal cytotoxic T-cell large granular
lymphocyte (T-LGL) expansions that are relatively common in
the blood of elderly patients (Khan et al, 2002). They may also
represent antigen-restricted T-LGL populations responding to
the MF tumor cells or to various therapeutic interventions. The
frequent presence of such T-LGL proliferations in blood can thus
complicate any T-cell clonality assay unless cell separations are
done prior to analysis. Given the low abundance of T-LGLs in
lymph node,T-cell clonality assays may be more useful in di¡er-
entiating benign dermatopathic lymphadenitis from early MF
involvement, especially in those cases where £ow cytometric
studies cannot be done.
Comparison of TCR-gamma PCR results at several involved
skin sites or serial analysis of skin biopsies over the course of dis-
ease may prove more useful in demonstrating a systemically dis-
seminated T-cell clone. Our group has demonstrated that early
MF may show signi¢cant clonal heterogeneity at di¡erent skin
sites (Vega et al, 2002). Furthermore, we showed that demonstra-
tion of an identical clonal gene rearrangement in multiple biopsy
specimens at the time of diagnosis can help predict patients who
will show clinical progression.
USE OF CLONALITY STUDIES TO IDENTIFY
PATHOGENETIC FACTORS IN MYCOSIS FUNGOIDES
Many cases of mycosis fungoides arise from preexisting in£amma-
tory dermatoses. Speci¢c antigenic and host immune interactions
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are believed to drive clonal expansion in the early stages of lym-
phomagenesis (Jackow et al, 1997). The response of any given
T-cell to a speci¢c antigen is largely encoded by the precise se-
quence of the complementarity-determining regions (CDR) on
the expressed T-cell receptor chains, which arise from di¡erential
joining of speci¢c V-D-J gene segments during recombination.
As such, we believe that the future direction of clonality studies
in MF will be directed to determining the speci¢c TCR se-
quences utilized by the neoplastic clone. This approach will give
information on both the presence of clonality and the speci¢c
variable-region utilized that may indicate di¡erent etiologies as-
sociated with speci¢c MF subtypes.
Given that most neoplastic and reactive T-cell populations ex-
press the alpha/beta TCR, clonality assays for this purpose need
to be focused on those genes rather than the TCR-gamma gene,
which is only rarely expressed as a result of out-of-frame recom-
binations during T-cell development. PCR analysis of either the
TCR-a or TCR-b is complicated by the large numbers of vari-
able region gene segments in these loci. Nonetheless, some studies
examining patterns of TCR-b rearrangement in MF by PCR
methods have been published (Assaf et al, 2000). PCR assays also
have the advantage of permitting subsequent direct sequencing of
the major ampli¢ed product(s) to allow con¢rmation of the
V- D- and J-segments utilized. This approach allows more careful
analysis of the exact CDR sequence and its possible role in bind-
ing common antigen targets (Jackow et al, 1997).
However, given the di⁄culties of a PCR-based approach, di-
rect detection of the speci¢cTCR-a/b protein present on the sur-
face of MF cells using variable region-speci¢c antibodies may
turn out to be a better strategy. This approach is feasible given
the fact that nearly all T-cell tumors continue to express surface
TCR at all stages. Given the di¡ering etiologies and variable clin-
ical course of MF,TCR-a/b clonality studies are likely to give the
most useful information both in establishing the diagnosis and in
providing pathogenetic and predictive information.
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